IDO1 and ovarian cancer: Second, the impact of tumoral IDO1 expression in ovarian cancer was not confined to the kynurenine pathway, but also mediated metabolic changes downstream of kynurenine, demonstrating a role for nicotinate, nicotinamide, purine and pyrimidine metabolic pathways.